EUVIMEDEUVIMED entdecken
Crossref

CMV reactivation after autologous stem cell transplantation: exploratory associations with transfusion burden and pre-transplant IMID exposure

Meral Ilgaz, Selma Gökahmetoğlu, Mehmet Çelik, Leylagül Kaynar

Journal of Current Hematology & Oncology Research · 13.11.2026 · 4 (4) · 135-139

DOI: 10.51271/jchor-0097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Current Hematology & Oncology Research, online erschienen am 13.11.2026. Verfasst von Meral Ilgaz und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate the incidence of CMV reactivation and disease after autologous stem cell transplantation (ASCT), identify risk factors with particular focus on erythrocyte transfusion burden and immunomodulatory drug (IMID) exposure, and determine high-risk subgroups warranting intensified surveillance.

Methods

Retrospective analysis of 188 CMV-seropositive ASCT recipients at Erciyes University between 2007–2016. CMV PCR was performed twice weekly for the first 100 days. Erythrocyte suspension (ES) and platelet suspension (PS) were analysed separately alongside combined transfusion burden. Fisher exact and chi-square tests were used (SPSS v16.0).

Results

CMV reactivation occurred in 44 patients (23.4%); 40 (90.9%) had asymptomatic DNAemia and 4 (9.1%) developed CMV disease. All reactivation events occurred within day +46. Refractory/progressive disease was associated with higher reactivation rates (50.0% vs 21.9%; p=0.056). ES ?6 units was strongly associated with CMV reactivation (62.5% vs 24.0%; odds ratio [OR] 5.28, 95% confidence interval [CI]: 1.20–23.18; p=0.028), while PS alone was not (p=0.429). IMID exposure was significantly protective in multiple myeloma (MM) patients (9.5% vs 27.4%; p=0.022) and the overall cohort (9.3% vs 27.6%; p=0.013). The protective effect was independent of IMID timing (pre-transplant 10.5% vs post-transplant 9.5%; p=1.000). Conditioning regimen was not associated with CMV reactivation (p=0.863).

Conclusion

Refractory disease and high erythrocyte transfusion burden are the strongest predictors of CMV reactivation after ASCT. ES is the primary transfusion-related determinant. The timing-independent protective effect of IMIDs suggests a durable NK-cell mediated immunological mechanism. Risk-stratified CMV monitoring is recommended for high-risk subgroups.

Zitieren

APA

Ilgaz, M., Gökahmetoğlu, S., Çelik, M., & Kaynar, L. (2026). CMV reactivation after autologous stem cell transplantation: exploratory associations with transfusion burden and pre-transplant IMID exposure. Journal of Current Hematology & Oncology Research, 4(4), 135-139. https://doi.org/10.51271/jchor-0097

Vancouver

Ilgaz M, Gökahmetoğlu S, Çelik M, Kaynar L. CMV reactivation after autologous stem cell transplantation: exploratory associations with transfusion burden and pre-transplant IMID exposure. Journal of Current Hematology & Oncology Research. 2026;4(4):135-139. doi:10.51271/jchor-0097

BibTeX
@article{Ilgaz2026,
  author = {Ilgaz, Meral and Gökahmetoğlu, Selma and Çelik, Mehmet and Kaynar, Leylagül},
  title = {CMV reactivation after autologous stem cell transplantation: exploratory associations with transfusion burden and pre-transplant IMID exposure},
  journal = {Journal of Current Hematology & Oncology Research},
  year = {2026},
  volume = {4},
  number = {4},
  pages = {135--139},
  doi = {10.51271/jchor-0097}
}
Kostenlos starten →